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Introduction: Immune tolerance induction (ITI) is the gold standard for eradication of 
factor VIII inhibitors in severe haemophilia A; however, it usually requires treatment 
for extended periods with associated high burden on patients and healthcare 
resources.
Aim: Review outcomes of ITI with recombinant factor VIII Fc fusion protein (rFVIIIFc) 
in patients with severe haemophilia A and high- titre inhibitors.
Methods: Multicentre retrospective chart review of severe haemophilia A patients 
treated with rFVIIIFc for ITI.
Results: Of 19 patients, 7 were first- time ITI and 12 were rescue ITI. Of 7 first-time 
patients, 6 had at least 1 high- risk feature for ITI failure. Four of 7 first- time patients 
were tolerized in a median of 7.8 months. The remaining 3 patients continue on rFVIIIFc 
ITI.	Of	12	rescue	patients,	7	initially	achieved	a	negative	Bethesda	titre	(≤0.6)	in	a	me-
dian of 3.3 months, 1 had a decrease in Bethesda titre and continues on rFVIIIFc ITI 
and 4 have not demonstrated a decrease in Bethesda titre. Of these 4, 3 continue on 
rFVIIIFc ITI and 1 switched to bypass therapy alone. Two initially responsive patients 
transitioned to other factors due to recurrence. Overall, 16 of 19 patients remain on 
rFVIIIFc (prophylaxis or ITI). For those still undergoing ITI, longer follow- up is needed 
to determine final outcomes. No adverse events reported.
Conclusions: Recombinant factor VIII Fc fusion protein demonstrated rapid time to 
tolerization in high- risk first- time ITI patients. For rescue ITI, rFVIIIFc showed thera-
peutic benefit in some patients who previously failed ITI with other products. These 
findings highlight the need to further evaluate the use of rFVIIIFc for ITI.
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1  | INTRODUCTION
Haemophilia A is a congenital disease caused by factor VIII (FVIII) defi-
ciency and results in spontaneous and traumatic bleeding.1 Recurrent 
bleeding leads to disability, affects quality of life and is potentially 
life- threatening.2 The standard treatment is intravenous FVIII con-
centrates administered prophylactically; however, episodic treatment 
is also used.3,4 Exposure to FVIII is associated with risk of inhibitor 
development, which renders replacement FVIII ineffective.4,5 The de-
velopment of inhibitors remains a key challenge in the treatment of 
haemophilia A and occurs in 25%- 35% of severely deficient patients 
(FVIII level <1%).6,7 In patients with high- titre inhibitors ([HTI]; >5 
Bethesda units [BU]), the standard of care is eradication of the inhib-
itor by immune tolerance induction (ITI). Although ITI regimens vary, 
most involve the regular administration of high doses of FVIII over 
months/years to tolerize the immune system so that FVIII can again 
be used prophylactically for haemostatic control. Bypassing agents 
(recombinant activated FVII [FVIIa] and activated prothrombin com-
plex concentrates [aPCCs]) are used to treat bleeding until tolerization 
is achieved.8-10 Results from previous studies reveal ITI success rates 
from 50% to 88%.8,10-18 In those who achieve successful ITI, it takes 
approximately 1- 2 years. For those who fail an initial course of ITI, res-
cue ITI is often tried, usually involving a change in factor type. The 
success rates for those who have previously failed ITI and are tried on 
rescue ITI is much lower, but data are lacking.
Historically, the purported risk factors for ITI failure include his-
torical	 peak	 inhibitor	 >200	BU,	 inhibitor	 titre	 of	 ≥10	BU	 at	 ITI	 start,	
age	≥8	years	at	 ITI	 start,	>2	years	between	 inhibitor	diagnosis	and	 ITI	
start, interruptions in ITI for longer than 2 weeks13,19,20 and previous ITI 
failure.12,13,16,21 For the most part, the risk factors for ITI failure are based 
on registry data and have not been well confirmed through randomized 
studies. A retrospective analysis by Nakar et al17 showed that inhibitor 
titre	≥10	BU	at	ITI	start	may	not	be	a	poor	risk	factor	if	ITI	is	started	early.
Given that treatment is not successful in a substantial number 
of patients who undergo ITI and that it may take significant time to 
achieve success at great risk, cost and inconvenience for patients, 
there is a major unmet need for agents that are associated with in-
creased response rates in a shorter time.22 Recombinant factor VIII Fc 
fusion protein (rFVIIIFc [Eloctate®, Bioverativ, Inc., Waltham, MA]) is 
the first extended half- life FVIII approved to treat haemophilia A.23-26 
There is limited experience for its use in ITI. A case series of 3 patients 
with haemophilia A using rFVIIIFc for ITI (in 1 case for rescue ITI) sug-
gested a more rapid time to tolerization compared with conventional 
FVIII products.27 This notion is supported by several preclinical studies 
showing that the Fc protein of rFVIIIFc has immunomodulatory prop-
erties.28-32 Here, we report findings associated with the use of rFVIIIFc 
for ITI in 19 patients via retrospective chart review.
2  | MATERIALS AND METHODS
A non- interventional retrospective chart review of ITI with rFVIIIFc in 
patients	with	severe	haemophilia	A	and	HTI	(≥5	BU)	was	conducted	
across 10 sites in the United States and Canada between 1 July 2014 
and 1 June 2017. Male patients of all ages with severe haemophilia 
A and HTI who had initiated treatment with rFVIIIFc for ITI, either 
as primary or rescue therapy, regardless of response, were included.
After institutional regulatory approval, de- identified clinical infor-
mation was collected via an electronic survey. Patients treated for the 
first time with ITI were evaluated for risk factors for ITI failure accord-
ing to the criteria listed earlier.13,19,20 Negative Bethesda titre was de-
fined	as	≤0.6	BU.	Tolerization	was	defined	as	negative	Bethesda	titre,	
normal	FVIII	 recovery	 (≥66%)	and	half-	life	 (≥6	hours).13 The primary 
objective of this study was to report the clinical characteristics and 
outcomes of ITI using rFVIIIFc. Results are summarized using descrip-
tive statistics; no inferential statistical analysis was conducted.
3  | RESULTS
3.1 | Study population
Nineteen patients were identified. Of these, 7 were receiving ITI 
for the first time and 12 were undergoing rescue ITI (Tables 1 and 
2). Median age at initiation of rFVIIIFc ITI was 1.3 years (range: 0.8- 
4.3 years) for first- time ITI and 6.4 years (range: 1.6- 12.6 years) for 
rescue ITI patients. Given their young ages, most patients had cen-
tral venous access devices (CVADs). This included 5 of 7 first-time 
ITI patients and 11 of 12 rescue ITI patients. Of first- time ITI pa-
tients, 3 were black, 3 were white, and 1 was Asian. For the rescue 
ITI patients, the majority were white (10/12), 1 was black, and 1 was 
“other” race.
First- time ITI patients had a median peak historical inhibitor (pre- 
ITI) titre of 151 BU (range: 11- 1126 BU) and a median inhibitor titre 
at start of rFVIIIFc ITI of 52 BU (range: 3- 1126 BU). At the start of ITI, 
6 of 7 first-time ITI patients had titres >10 BU; 4 of these 6 had titres 
>50 BU. The median time from inhibitor diagnosis to start of rFVIIIFc 
ITI was 4.4 weeks (range: 0- 41 weeks).
For rescue ITI patients, the mean number of prior ITI courses with 
other FVIII products was 2.6 (range: 1- 5) and the median time from 
inhibitor diagnosis to the start of rFVIIIFc ITI was 5.5 years (range: 0.8- 
12 years). These patients had a median peak historical inhibitor (pre- 
ITI) titre of 124 BU (range: 8- 1024 BU) and a median inhibitor titre at 
start of rFVIIIFc ITI of 24.2 BU (range: 0.6- 237 BU). FVIII genotypes 
for 18 of the 19 patients are shown in Tables 1 and 2.
3.2 | First- time ITI patient outcomes
At the time of data collection, 4 of 7 patients undergoing first- time ITI 
with rFVIIIFc (Table 1) were tolerized and had transitioned to rFVIIIFc 
prophylaxis. Three of these 4 patients achieved a negative Bethesda 
titre	and	normal	FVIII	recovery	and	half-	life	(≥6	hours);	as	such,	they	met	
the definition of tolerization at 5, 7 and 9 months. These patients were 
all on a daily rFVIIIFc (85- 200 IU/kg) ITI regimen. The fourth patient was 
considered tolerized by the treating physician at 14.8 months based on 
a negative inhibitor titre and having been transitioned to prophylaxis; at 
the time of data collection, that patient was 13 months post- completion 
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of rFVIIIFc ITI and he continued to have a negative Bethesda titre on 
rFVIIIFc	prophylaxis.	A	half-	life	≥6	hours	was	also	reported	at	that	time.	
This patient had been on a 3-times-per-week (50 IU/kg) ITI regimen.
Among these 4 patients, the median time to attain a negative 
Bethesda titre was 27.7 weeks (range: 4.1- 64 weeks) and the median 
time to reported tolerization was 33.9 weeks (7.8 months; range: 21- 
64 weeks). For the 3 patients treated with daily rFVIIIFc, tolerization 
took only 29 weeks (6.7 months; range: 20.6- 38 weeks), whereas it 
took 64 weeks (14.8 months) for the patient treated with a 3-times-
per-week ITI regimen.
Of the remaining patients (n = 3), 2 had a decrease in Bethesda 
titre (from 32 to 18 BU and from 378 to 23 BU after 18 and 58 weeks 
of ITI, respectively), and 1 patient had an initial increase in Bethesda 
titre from 3 to 16 BU after 15 weeks. He was switched to ITI with 
another factor but remained unresponsive and after 27 weeks was re-
sumed on rFVIIIFc ITI, which has now been ongoing for 7 weeks; his 
most recent Bethesda titre has fallen to 5 (Table 1). This patient was 
reported to be poorly compliant with ITI.
All 7 first-time ITI patients continue on rFVIIIFc ITI or prophylaxis.
3.3 | Rescue ITI patient outcomes
Seven of 12 previously failed patients undergoing rescue ITI (Table 2) 
achieved Bethesda negativity with rFVIIIFc ITI. Median time to attain 
a negative titre was 14.1 weeks (range: 3- 67.6 weeks). Three of these 
7 patients remain Bethesda negative and continue on rFVIIIFc ITI 
(n = 2) or have been weaned to rFVIIIFc prophylaxis (n = 1). The other 
4 patients who initially achieved a negative titre later developed a titre 
>0.6 BU. Of these, 2 continue on rFVIIIFc ITI and 2 were transitioned 
to ITI with other factors (Table 2).
Of the 7 patients achieving Bethesda negativity, 3 also achieved 
normal FVIII recovery at 3, 14 and 65 weeks and a fourth patient 
reached normal FVIII half- life at 27 weeks. Recovery and half- life were 
not available in others (Table 2).
Of the remaining 5 of 12 rescue patients, one had a decrease 
in Bethesda titre (from 36 to 22 BU after 10 weeks) and in 4, the 
Bethesda titre either remained unchanged or increased while on ITI 
(Table 2). Of these 5 patients, 4 continue on rFVIIIFc ITI and 1 was 
removed from ITI and placed on bypass therapy alone.
3.4 | Dosing outcomes, bypass agent use and current 
treatment status
The patient population assessed in this study received a wide range/
timing of doses (Tables 1 and 2). A trend towards rapid negative in-
hibitor titres was seen with higher doses administered daily. Five of 5 
patients (1 first-time ITI and 4 rescue ITI) who received a daily rFVIIIFc 
dose	of	≥130	IU/kg	achieved	a	negative	Bethesda	titre	at	a	median	of	
28 weeks. Eighteen of 19 patients used bypass agents concurrently 
with rFVIIIFc ITI; 14 were primarily on prophylaxis (9 with aPCCs and 
5 with rFVIIa), and 4 were treated on demand with rFVIIa.
Overall, 16 of 19 patients remained on rFVIIIFc (prophylaxis or ITI) 


































































































































































































































































































































































































































































































































































































































































































































































































































248  |     CARCAO et Al.
3.5 | Safety
No adverse events, including no thromboembolisms, were reported. 
Six surgeries were performed while patients were undergoing ITI 
under the cover of bypassing agents; all of them without interruption 
of rFVIIIFc ITI (knee synovectomy, intracranial neurosurgical evacu-
ation, and 4 Port- A- Cath insertions). Inhibitor titres during surgeries 
were not collected for this study.
4  | DISCUSSION
Eradication of inhibitors using ITI is the gold standard for patients 
with HTI in haemophilia A and is the only therapy that can allow the 
patient to return to a prophylactic FVIII regimen. Studies have shown 
that long- term outcomes, including mortality, are greatly improved 
if inhibitors are eradicated and, furthermore, the long- term costs 
associated with inhibitor therapy would likely be reduced by early 
eradication.22,33,34
The main limitations of ITI with conventional factor replacement 
therapies are the need for frequent factor infusions, which in most 
young children necessitates indwelling CVAD; the decreased quality 
of life while on ITI; and enormous healthcare utilization costs given 
the high doses of factor required.35 All of these are compounded by 
the extended duration of treatment needed to achieve tolerization. If 
ITI required less time, then its drawbacks would be greatly reduced. 
A FVIII product regimen that could successfully achieve a more rapid 
time to tolerization is key to clinical success and improving patient 
outcomes.
Registry data have indicated that inhibitor titre at start of ITI is 
a predictor of success, with titres <10 BU associated with better 
outcomes.36,37 Despite this, 6 of 7 patients undergoing first- time ITI 
in this study started ITI with titres >10 BU. Four of these 6 patients 
achieved inhibitor tolerization. ITI in all 7 patients was started a 
median of 4.4 weeks from inhibitor diagnosis, without waiting for the 
inhibitor titre to drop to <10 BU.
Of late, the notion of inhibitor level >10 BU at start of ITI being 
considered a poor prognostic factor has been challenged, as very 
good success rates in patients starting ITI with inhibitor titres >10 BU 
have been reported when ITI has been commenced soon after 
inhibitor detection.17 Conceivably, the quick initiation of ITI may have 
contributed to the success of ITI in this study. As there was evidence 
of rapid tolerization, an early ITI initiation approach with rFVIIIFc 
warrants prospective study.
A peak inhibitor titre >200 BU/mL is recognized as an independent 
risk factor for ITI failure.19,36,37 All 3 patients in the first- time ITI group 
that had peak titres >200 BU/mL had a decrease in inhibitor titres 
after initiating rFVIIIFc ITI (Table 1). This includes a patient with a peak 
level of 1126 BU/mL who became Bethesda negative at 31 weeks and 
completely tolerized at 38 weeks. That patient has now transitioned 
to prophylaxis with rFVIIIFc. Lower risk patient groups may benefit 
as well. Of the first- time ITI patients who were tolerized with a daily 
factor regimen, the individual with the lowest peak titre (51 BU) 
reached a negative Bethesda titre in 1 month and fully tolerized in 
5 months, making them the fastest of all first- time patients to tolerize, 
highlighting a potential benefit of even faster inhibitor eradication in 
lower risk patients.
The rescue ITI patient group was a heavily pretreated cohort with 
an average number of prior ITI treatments of 2.6 and a median time 
from inhibitor diagnosis to start of rFVIIIFc ITI of 5.5 years. Despite 
this, rFVIIIFc demonstrated therapeutic benefit of inhibitor eradication 
in several of these patients. For example, one patient who failed 5 prior 
ITI regimens with different factors over a span of 5 years successfully 
reached a negative Bethesda titre and a normal FVIII recovery with 
rFVIIIFc ITI (FVIII half- life was not reported) and has now been 
weaned to rFVIIIFc prophylaxis. However, most rescue patients in this 
study were still undergoing rFVIIIFc ITI at the time of data collection, 
and, therefore, a longer follow- up is needed to determine their final 
outcomes.
A variety of ITI protocols have been developed that include a wide 
range of dosing regimens.38 In the International Immune Tolerance 
Induction Trial (I- ITI),13 higher doses during ITI (200 IU/kg/d) achieved 
tolerization	 (negative	 Bethesda	 titer,	 normal	 FVIII	 recovery	 [≥66%]	
and	half-life	[≥6	hours])	significantly	faster	than	the	low-	dose	regimen	
did (50 IU/kg 3 times per week). In this retrospective review, there 
was also a trend towards achieving a negative Bethesda titre faster 
with	higher	rFVIIIFc	doses	(≥130	IU/kg)	administered	on	a	daily	basis.
In contrast to the first- time ITI rFVIIIFc- treated patients in this 
chart review, the I- ITI included first- time ITI patients with a more 
favourable risk profile. The median peak inhibitor titre for the I- ITI 
patients was 22 BU compared with 151 BU for the rFVIIIFc ITI patients 
presented here. The median titre at the start of ITI was 5.5 BU in the 
I- ITI as opposed to 52 BU for the rFVIIIFc ITI patients. In addition, 
the I- ITI excluded patients with peak titres >200 BU. In contrast, 43% 
of the first- time ITI patients in our cohort had peak titres >200 BU 
and 86% had a titre >10 BU at the start of rFVIIIFc ITI. Lastly, 3 of 
the 7 first-time ITI patients reported here were of black race, which is 
associated with a lower rate of ITI success.39 Based on the above, we 
speculate that the 7 first-time ITI patients reported here constitute 
a select group of high- risk patients in whom clinicians tried rFVIIIFc 
hoping that it would be more successful than ITI using conventional 
FVIII products.
Although first- time ITI patients in our study were a higher risk 
group for ITI failure (mainly on the basis of their high peak titres pre- 
ITI), 4 of the 7 first-time patients still quickly achieved tolerization in 
a median of 7.8 months. In contrast, for the I- ITI study patients (who 
constituted a lower risk group for ITI failure), ITI took a median of 10.6 
and 15.5 months (for high- and low- dose ITI regimens, respectively) to 
achieve tolerization.13
A more comparable high- risk cohort of patients was evaluated 
by Oldenburg et al18 in which the use of a VWF- containing plasma- 
derived FVIII regimen for high- risk ITI patients was studied. The inves-
tigators reported a median time to tolerance of 20 months for high- risk 
first- time ITI patients, as measured via Kaplan- Meier method,18 which 
was higher than what was observed in our high- risk first- time ITI 
rFVIIIFc- treated patients. Because of the retrospective nature of our 
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study, however, we recognize the limitations in comparing our data 
with these other cohorts.
We speculate that rFVIIIFc may have properties that uniquely pro-
mote tolerization.32 In a mouse model of haemophilia A, rFVIIIFc had 
reduced immunogenicity, promoted FVIII- specific tolerance and in-
duced an increase in regulatory T cells and tolerance- related genes.31 
Furthermore, transplacental transfer of Fc fusion proteins with 
immunodominant A2 and C2 FVIII domains, as well as treatment with 
rFVIIIFc in haemophilia A mice, has been shown to induce tolerance 
and reduce immunogenicity in the progeny.29,30 In addition, epitopes 
in the Fc fragment are known to upregulate regulatory T cells, which 
can result in tipping the balance towards tolerance over immunoge-
nicity.28 These data are consistent with prior case reports in which 4 
patients had been successfully treated with rFVIIIFc for inhibitors27,40 
and with the case series described here.
Immune tolerance induction is a substantial economic burden in 
the healthcare utilization system, with high costs for both the FVIII and 
bypassing agents used. One study estimated that the average monthly 
costs of ITI were $103,000 ($78,000 for standard half-life FVIII and 
$25,000 for bypassing agents) or $1.2 million per patient per year.35,41 
What most impacts on the cost of ITI is its long duration. A US claims 
data analysis indicated that the real- world average duration of ITI with 
conventional FVIII products was 18.7 months.35 The data presented 
in our study indicate that rFVIIIFc may offer a more rapid time to tol-
erization; this could in turn be associated with a potential decrease 
in long- term bypassing agent use and improvements in the excessive 
financial burden associated with ITI.
The main limitations of this study were its retrospective nature, 
its limited patient population and it being a case series, which may 
lead to potential biases (including reporting bias). The relatively 
rapid achievement of tolerization in first- time ITI patients could be 
attributed to the use of rFVIIIFc but also could be due to the early 
initiation of ITI soon after inhibitor development. Because drawing 
definitive conclusions from a retrospective non- controlled case se-
ries is not possible, clinical studies will be needed to generate these 
data in a prospective manner.
5  | CONCLUSIONS
Collectively, our results show that ITI with rFVIIIFc is possible and 
can result in inhibitor eradication and successful ITI in many patients 
at high risk for ITI failure undergoing first- time ITI and in some pa-
tients undergoing rescue ITI. Furthermore, rFVIIIFc ITI demonstrated 
a rapid decrease in Bethesda titres and rapid time to tolerization in the 
majority of patients receiving first- time ITI despite their risk profile. 
For rescue ITI, it is more difficult to draw conclusions as most of these 
patients were still undergoing ITI with rFVIIIFc at the time of data 
collection. However, some patients receiving rescue ITI did appear 
to derive therapeutic benefit in that they either achieved Bethesda 
negativity or showed significant drops in inhibitor titres. This was 
particularly	 the	 case	when	 higher	 rFVIIIFc	 dosing	 (≥130	IU/kg)	was	
administered daily. These findings highlight the need for additional 
data; 2 prospective trials are currently being initiated using rFVIIIFc 
for ITI in patients with haemophilia A with inhibitors (NCT03093480 
and NCT03103542).
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